Gliadel Wafer + Temozolomide

Phase 2UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 31/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Newly Diagnosed Supratentorial Malignant Glioma

Conditions

Newly Diagnosed Supratentorial Malignant Glioma

Trial Timeline

Sep 1, 2002 → Apr 1, 2008

NCT ID

NCT00283543

About Gliadel Wafer + Temozolomide

Gliadel Wafer + Temozolomide is a phase 2 stage product being developed by Eisai for Newly Diagnosed Supratentorial Malignant Glioma. The current trial status is unknown. This product is registered under clinical trial identifier NCT00283543. Target conditions include Newly Diagnosed Supratentorial Malignant Glioma.

What happened to similar drugs?

0 of 5 similar drugs in Newly Diagnosed Supratentorial Malignant Glioma were approved

Approved (0) Terminated (1) Active (4)

🔄Olaparib 300mg tabletsAstraZenecaPhase 3

🔄Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimenAmgenPhase 3

🔄Elranatamab + Lenalidomide (Revlimid®) + Daratumumab SC (Darzalex) + Bortezomib (Velcade®) + DexamethasonePfizerPhase 3

❌Lenalidomide + Dexamethasone + ElotuzumabBristol Myers SquibbPhase 3

🔄Bortezomib + Isatuximab + Iberdomide + Lenalidomide + DexamethasoneBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00283543	Phase 2	UNKNOWN	Sep 1, 2002	Apr 1, 2008	Newly Diagnosed Supratentorial Malignant Glioma

Competing Products

18 competing products in Newly Diagnosed Supratentorial Malignant Glioma

See all competitors

Product	Company	Stage	Hype Score
PLX3397 + Temozolomide	Daiichi Sankyo	Phase 1/2	32
Olaparib 300mg tablets	AstraZeneca	Phase 3	44
Pembrolizumab	Merck	Phase 2	39
Drug (including placebo)	Merck	Phase 1	21
Cilengitide	Merck	Phase 2	31
[177Lu]Lu-NeoB + [68Ga]Ga-NeoB	Novartis	Phase 1	33
BKM120 + Trastuzumab + Paclitaxel + BKM120 Placebo	Novartis	Phase 2	35
Tecentriq 1200 MG in 20 ML Injection + H3K27M peptide vaccine	Roche	Phase 1	33
Zenapax	Roche	Phase 2	35
Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimen	Amgen	Phase 3	47
Elranatamab + Lenalidomide (Revlimid®) + Daratumumab SC (Darzalex) + Bortezomib (Velcade®) + Dexamethasone	Pfizer	Phase 3	47
Elranatamab + Daratumumab + Lenalidomide	Pfizer	Phase 2	42
Lenalidomide + Dexamethasone + Elotuzumab	Bristol Myers Squibb	Phase 3	32
Bortezomib + Isatuximab + Iberdomide + Lenalidomide + Dexamethasone	Bristol Myers Squibb	Phase 3	47
Isatuximab-Irfc 20 MG/ML [Sarclisa] + Lenalidomide + Dexamethasone Oral	Sanofi	Phase 2	39
Mebendazole	Brain Biotech	Phase 1	19
Balstilimab + Botensilimab + Liposomal Doxorubicin	Agenus	Phase 2	32
HLA-A2 restricted glioma antigen peptides vaccine + Poly-ICLC	Brain Biotech	Phase 1	19